

Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials

Elliot Dinetz, MD; Edwin Lee, MD

ABSTRACT

Objective • This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Ta1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in more than 30 trials. The focus was on Ta1's application in COVID-19, autoimmune conditions, and cancer treatment, with implications for future considerations.

Methods • We systematically searched articles relevant to critical studies on COVID-19, infectious diseases, cancer, and autoimmune diseases indexed on Pubmed, Google Scholar, and Cochrane Library. Our focus was on evaluating the safety and efficacy of Ta1 in human subjects. Clinical trials conducted worldwide involving diverse populations were analyzed to assess the safety and effectiveness of Ta1. The review examines explicit outcomes in over 11 000 human subjects, emphasizing its role in addressing COVID-19, autoimmune conditions, and cancer treatment.

Results • Contrary to the FDA's restriction on Ta1 and 21 additional peptides in 2023, our analysis reveals consistent evidence of Ta1's safety and efficacy. The peptide has demonstrated significant effectiveness in treating various conditions, including COVID-19, autoimmune disorders, and cancer. This review summarizes conclusions drawn from a comprehensive examination of clinical trials worldwide.

Conclusions • Based on substantial evidence from clinical trials, Ta1 emerges as a well-tolerated and effective immune modulator. The FDA's restriction appears unfounded, as Ta1 has shown safety and efficacy beyond the initially specified conditions. Urgent attention and intervention are warranted to ensure the continued availability of this life-saving peptide through prescription. Therefore, it is recommended that the FDA permits 503A compounding pharmacies to compound Ta1, considering its potential to treat a variety of conditions effectively. (*Altern Ther Health Med.* 2024;30(1):6-12).

Elliot Dinetz, MD, Voluntary Associate Professor, Department of Family Medicine, Miller School of Medicine University of Miami, Timeless Health Medical Center, Miami, Florida, United States. **Edwin Lee, MD**, Assistant Professor of Internal Medicine at the University of Central Florida College of Medicine, FACE Institute for Hormonal Balance, Orlando, Florida, United States.

Corresponding author: Edwin Lee, MD
E-mail: info@DrEdwinLee.com

INTRODUCTION

Thymosin Alpha 1 (Ta1) is a 28-amino acid peptide derived from calf thymus tissue by Dr. Allan L. Goldstein in the 1970s.¹ The synthetic form of this peptide, known as thymalfasin, has received approval in more than 35 countries for treating hepatitis B and C and as an immune enhancer in various diseases.² Despite being unapproved by the FDA in the USA, Ta1 gained FDA orphan drug approval from 1991 to 2006, allowing compassionate use in four clinical trials addressing conditions such as hepatitis B, thymus gland

absence in children, DiGeorge Syndrome, hepatocellular carcinoma, and malignant melanoma.³

Ta1 plays a crucial role in immune system regulation, exerting influence over various immune cell subsets, including dendritic cells, T cells, and natural killer cells, integral to both innate and adaptive immunity.⁴ Ta1 has been studied extensively for decades, showing its immunomodulatory effects, and is typically administered via subcutaneous injection, though intravenous administration is also possible. It has demonstrated a promising impact in enhancing T cell function and improving immune responses in both animal and human studies, and these findings hold significance for the treatment of diverse medical conditions, especially those associated with immune dysfunction. Human clinical trials have demonstrated that Ta1 possesses antiviral, autoimmune-mitigating, and anti-cancer properties, thereby suggesting its role in contributing to the treatment of widespread medical conditions.

This study specifically investigated the therapeutic domains of Ta1, examining its antiviral, autoimmune mitigating, and anti-cancer properties. The objective was to assess the contribution of Ta1 to the treatment of prevalent

Table 1. Safety Trials on Ta1 for Various Infectious Diseases (8075 Patients)

Author	Description	Sample Size	Adverse Effects
Shang et al. 2023 ³	Analysis of multiple studies on the effectiveness of Ta1 treatment for COVID-19.	5352	No allergic reactions or drug eruptions
Tuthill et al. 2023 ⁸	Application of Ta1 to patients on hemodialysis coinciding with COVID-19 infection.	194	No differences between the Ta1 group and placebo group with serious adverse effects
Wang et al. 2021 ¹⁰	Ta1 treatment in hospitalized patients with COVID-19.	275	No side effects were noted
Li et al. 2021 ⁶¹	Gender-specific markers in COVID-19 infected patients treated with Ta1.	127	No side effects were noted
Wu et al. 2013 ¹¹	Ta1 for severe sepsis: a multicenter, single-blind, randomized and controlled trial	361	No Ta1 severe adverse event was reported
Liu et al. 2016 ⁶²	Review of randomized controlled trials on Ta1 treatment in sepsis	530	No reported severe adverse event or treatment discontinuation with Ta1
Andreone et al. 1996 ¹⁷	Ta1 for the treatment of chronic hepatitis C	19	No side effects were noted
Rasi et al. 1996 ¹⁸	Ta1 and interferon for the treatment of chronic hepatitis C	15	No side effects were noted
Moscarella et al. 1998 ¹⁹	Ta1 and interferon for the treatment of chronic hepatitis C	17	No side effects were noted
Sherman et al. 1998 ²²	Ta1 and interferon for the treatment of chronic hepatitis C	35	No side effects were noted
Ciancio et al. 2012 ²⁰	Ta1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin	275	No side effects were noted
Poo et al. 2008 ²³	Ta1 with peginterferon alfa-2a and ribavirin for chronic hepatitis C not responsive to IFN/ribavirin	40	No side effects were noted
You et al. 2006 ¹³	Ta1 and interferon-alpha in the treatment of chronic viral hepatitis B	62	3 patients had local site irritation. No other side effects were reported
Peng et al. 2020 ¹⁴	Meta-analysis on Ta1 plus Entecavir in Hepatitis B cirrhosis	572	Entecavir plus Ta1 led to a significant decrease in adverse events compared with monotherapy.
Lin et al. 2002 ⁶³	Ta1 and famciclovir in chronic Hepatitis B	32	No side effects were noted
Zhang et al. 2009 ¹⁶	Meta-analysis on Ta1 plus Lamivudine in chronic Hepatitis B	295	No side effects were noted
Ramachandran et al. 1996 ¹⁴	Ta1, interleukin-2, and zidovudine in HIV	12	No side effects were noted
Garaci et al. 1998 ²⁵	A randomized controlled study of zidovudine, thymosin-α1 and interferon-α in HIV	92	No side effects were noted
Chadwick et al. 2003 ²⁶	Thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy	13	No side effects were noted
Total Number of Patients: 8318			

Note: The table summarizes safety trials on Ta1 involving 8075 patients across various infectious diseases, including COVID-19, hepatitis, and HIV. The trials demonstrated a favorable safety profile with no significant adverse effects reported. The studies cover a range of conditions, indicating the potential of Ta1 in diverse therapeutic applications.

Table 2. Safety Trials on Ta1 for Cancer Treatment (2742 Patients)

Author	Description	Sample Size	Adverse Effects
Linye et al. 2021 ⁶⁴	Ta1 therapy with Hepatitis B related hepatocellular carcinoma	468	No side effects were noted
Shuqun et al. 2004 ⁴⁵	Combination transcatheter hepatic arterial chemoembolization with Ta1 on recurrence prevention of hepatocellular carcinoma	18	No adverse effects were reported.
Liang et al. 2016 ⁶⁴	Ta1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma	146	No adverse effects were reported
Stefanini et al. 1998 ⁴⁶	Ta1 and Transcatheter arterial chemoembolization in hepatocellular carcinoma	12	No side effects were noted
Shuqun et al. 2006 ⁶⁵	Ta1 and lamivudine for Hepatitis B associated hepatocellular carcinoma	16	No adverse effects were reported
Lopez et al. 1994 ³⁹	Ta1, interleukin-2 and dacarbazine therapy in metastatic melanoma	46	No side effects were noted
Rasi et al. 2000 ⁶⁶	Ta1, interleukin-2 and dacarbazine therapy in metastatic melanoma	20	No side effects were noted
Maio et al. 2010 ⁴¹	Phase 2 trial with Ta1 Dacarbazine with or without interferon-alpha for stage 4 melanoma	488	No adverse effects were reported.
Danielli et al. 2018 ⁴²	Ta1 therapy with immune checkpoint Ab in metastatic melanoma	61	No adverse effects were reported. Follow up for more than 4 years
Schulof et al. 1985 ²⁹	Randomized trial of Ta1 in non-small cell lung cancer	42	No adverse effects were reported.
Garaci et al. 1995 ³⁰	Phase 2 trial with Ta1 and chemimmunotherapy for advanced non-small cell lung cancer	56	Overall, treatment was well tolerated
Salvati et al. 1996 ³¹	Phase 2 trial with Ta1 and low dose interferon alpha after ifosfamide in non-small cell lung cancer	22	Hematologic toxicity was reduced with Ta1
Jiang et al. 2011 ³²	Meta-analysis Ta1 plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer	320	No drug-related serious adverse events
Guo et al. 2021 ³⁴	Long-term survival with Ta1 therapy with non-small cell lung cancer after margin-free resected surgery	1027	No drug-related serious adverse events and no adverse events that led to Ta1 discontinuation
Dou et al. 2011 ³⁵	Patients with invasive ductal carcinoma were evaluated in 2 groups, one receiving hormonal therapy and the other 4 cycles of chemotherapy, where all received Ta1	36	There are side effects from a depressed immune system, including less pain
Wenbo et al. 2023 ⁶⁷	A prospective randomized controlled study of conventional and high dose Ta1 plus chemotherapy compared to chemotherapy alone	200	no discontinuation of treatment with reduced incidence of postoperative complications
An et al. 2004 ³⁶	Clinical trial of Ta1 with chemotherapy for patients with colorectal cancer to reduce neurotoxicity	22	Ta1 reduced the neurotoxicity side effects with chemotherapy

Note: The table summarizes safety trials on Ta1 for cancer treatment, providing information on sample sizes, adverse effects, and references for each study. The total number of subjects across all studies is 3000.

medical conditions. Importantly, in its role in immune system regulation, peptide therapy, including Ta1, did not exhibit adverse severe reactions or known toxicity. The primary reported adverse event involved local injection site irritation, and most reported events were mild and transient and were also reviewed. Our results contribute to understanding the safety profile and potential benefits of Ta1 in clinical settings.

METHODS

This study employed a comprehensive search for articles relevant to critical studies on COVID-19 and other infectious diseases, including cancer and autoimmune diseases, indexed on Pubmed, Google Scholar, and Cochrane Library. The primary focus was to present an evaluation of the safety and efficacy of Ta1 in human subjects. Human trials utilizing Ta1

that could not be located or translated into English were excluded to maintain the study's integrity. Two tables were constructed to provide a detailed summary of reported side effects: Table 1 presented the side effects of Ta1 in Covid-19 and other infectious diseases, while Table 2 listed the peptide's side effects when used in the context of cancer.

DISCUSSION

Effectiveness of Ta1 Against COVID-19 and Infectious Disease

In the wake of the recent COVID-19 pandemic, which exposed the susceptibility of immune dysfunction, it becomes imperative to explore innovative approaches to enhance immune function. In January 2023, a meta-analysis encompassing over 5000 patient outcomes across nine studies investigated the effects of treatment with Ta1

compared to control or standard care. Notably, no serious adverse events related to Tα1 were reported. Subanalysis further revealed a mortality benefit among individuals aged 60 and above, those with critical COVID-19, and cases where Tα1 administration commenced early as opposed to late stages.⁵

One study⁶ involved a pilot trial of Tα1 for the treatment of hypoxemic COVID-19 patients. Among the 23 patients receiving Tα1, any reported side effects were explicitly considered unrelated to Tα1. Additionally, a separate retrospective review⁷ of 76 patients who received this peptide demonstrated a significant reduction in mortality and improved CD4+ T-cells, with no serious adverse events or discontinuation of therapy reported.

Furthermore, a randomized trial⁸ involving 194 patients from 5 dialysis centers revealed that those who received Tα1 demonstrated efficacy in preventing the progression of COVID-19. The safety monitoring board reported no more serious adverse events than in the control group and observed fewer deaths. In late 2023, a systematic review⁹ of 8 studies indicated that moderate to critical COVID-19 patients receiving Tα1 therapy experienced significantly lower mortality, with no mention of intolerance to this treatment. Notably, studies that did not find statistically significant benefits from using Tα1, such as the one conducted by Wang et al.¹⁰, reported no serious adverse events or concerns leading to the discontinuation of therapy among the 149 participants in the Tα1 arm of the trial.

It is well-established that numerous infectious diseases lead to high mortality rates despite the current proven standard of care. Tα1 has been investigated in such contexts. In a multicenter randomized controlled trial¹¹ involving 361 patients with sepsis, no Tα1-related severe adverse events were reported, and therapy was not discontinued among the 181 treated, as reported by the university supervising the study. Subsequently, a meta-analysis¹² of 12 studies on septic patients found no Tα1-related adverse effects in two of the studies, with no mention of toxicity in the remaining trials, involving a total of 1480 participants. The conclusion of the meta-analysis highlighted lower mortality rates and recommended considering this peptide in future treatment strategies.

Concerning hepatitis B, numerous human trials employing Tα1 to treat hepatitis B have demonstrated significant benefits without serious side effects.^{13,14} A study¹⁵ investigating the combination of Tα1 and famciclovir revealed a greater reduction in HBV-DNA levels compared to famciclovir alone. Serological clearance of HBeAg was associated with the activation of HBV-specific Th1 cells, and no side effects were reported with Tα1.

Similarly, a meta-analysis¹⁶ encompassing eight trials (583 patients in total, with 295 receiving Tα1 and lamivudine) indicated that the combination of lamivudine and Tα1 was significantly superior to lamivudine alone in terms of ALT normalization rate, virological response rate, and HBeAg seroconversion rate. No adverse side effects were reported

with Tα1 in this meta-analysis. In another meta-analysis,¹⁴ involving 310 patients (155 in the Entecavir plus Tα1 group and 155 in the Entecavir alone group) treated for 24 weeks, it was demonstrated that Entecavir plus Tα1 was significantly superior to Entecavir monotherapy in achieving undetectable HBV DNA levels. This meta-analysis also affirmed the safety of Tα1. Collectively, these studies consistently demonstrate positive outcomes and the safety of using Tα1 as a peptide treatment.

Earlier, when researchers initially explored the use of Tα1 to treat hepatitis C, a study¹⁷ involving 19 patients found that Tα1 alone was not beneficial but was well-tolerated. However, the combination of Tα1 with Interferon in chronic hepatitis C demonstrated greater effectiveness than interferon alone. In an open-label trial,¹⁸ 15 patients treated with a combination of Tα1 and Interferon for chronic Hepatitis C exhibited significant improvement. Six months after initiating treatment, seven patients (47%) tested negative for HCV RNA, and at the completion of the one-year trial, 11 patients (73%) had negative HCV RNA, including two individuals who had previously failed standard IFN treatment.

In another study,¹⁹ 17 patients with chronic hepatitis C underwent treatment with a combination of Interferon and Tα1 (1 mg twice weekly), while another 17 patients received only Interferon. The treatment duration for all patients was 6 months, with a subsequent 12-month follow-up period. The results indicated that combination therapy demonstrated significantly higher efficacy than monotherapy in achieving biochemical and virologic end-of-treatment responses with no reported unwanted side effects.

In another study,²⁰ 552 patients with hepatitis C who had previously shown no response to interferon and ribavirin were randomly assigned to groups receiving either interferon, ribavirin, and Tα1 or interferon, ribavirin, and a placebo. Among them, 275 patients received Tα1 at a dose of 1.6 mg subcutaneously twice a week for 48 weeks. The inclusion of Tα1 in the standard care regimen did not lead to a reduction in HCV RNA levels, but it was well tolerated with no reported adverse reactions. Despite these less favorable outcomes, a separate case was documented involving two Koreans with hepatitis C, unresponsive to interferon and ribavirin, who exhibited a positive response to Tα1.²¹

Considering the earlier findings related to Tα1 and Interferon, three extensive studies were undertaken, including the United States Phase III trial, the Mexican pilot study, and the European Phase III trial. These studies aimed to assess the efficacy of Tα1 administered at a dose of 1.6 mg subcutaneously twice a week in challenging-to-treat patients with chronic hepatitis C who had not responded to previous antiviral therapy. The European Phase III study, comprising 275 patients, demonstrated that the addition of Tα1 to Interferon and ribavirin significantly reduced the relapse rate. Notably, Tα1 was found to be safe for use in the context of hepatitis C.²⁰⁻²¹

The USA Phase III trial involved 109 patients, with 35 receiving Interferon and Tα1, 37 receiving Interferon, and 37 receiving a placebo. None of the groups received ribavirin. In

the Interferon and Ta1 group, 3 patients dropped out due to noncompliance with the protocol, a job change incompatible with the study regimen, and loss to follow-up. Ta1 was well-tolerated, and the combination of Ta1 and Interferon demonstrated lower HCV RNA, lower ALT, and improved histological activity index compared to Interferon alone.²² A Mexican study by Poo et al.²³ evaluated triple therapy, including Ta1 with Interferon and ribavirin, in 40 Hispanic chronic hepatitis C patients who were non-responders. At the end of the 48-week study, nearly 50% had undetectable HCV RNA, and Ta1 was well-tolerated. Overall, Ta1 has been shown to be safe for use in hepatitis C.

In a clinical trial²⁴ involving patients with HIV, Ta1 demonstrated an increase in CD4 counts, specifically when administered in combination with zidovudine along with either interleukin-2 or interferon- α . A small study comprising 12 patients with HIV, given zidovudine, interleukin-2, and Ta1, exhibited no increase in HIV activation while showcasing an improvement in the CD4 count. Importantly, in this study, the peptide was well-tolerated. A multicenter Phase II randomized study²⁵ involving 92 patients with HIV revealed that the triple combination of zidovudine, Ta1, and alpha interferon resulted in a greater reduction in HIV RNA levels and an enhanced improvement in CD4 counts compared to other groups in the study.

In a randomized phase II clinical trial²⁶ conducted in 2003, highly active antiretroviral therapy (comprising multiple combinations of non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors) was employed with Ta1 to assess its potential impact on improving CD4 counts. A total of 13 patients with HIV, already on highly active antiretroviral therapy, with viral loads below 400 copies/ml and CD4 counts below 200 cells/ μ , received Ta1 for 12 weeks. Unfortunately, no improvement in their CD4 count was observed during this short 12-week study. It is important to note that the absence of enhanced CD4 counts could be attributed to the small sample size and the relatively brief duration of the study. However, Ta1 was well-tolerated in this trial.

Effectiveness of Ta1 Against Cancers

Early cancer investigations focused on Ta1 and its precursor, Thymosin fragment 5, conducted by the National Cancer Institute. These studies initially highlighted the favorable safety profile of thymic-based treatments, leading to the commencement of large-scale studies. Numerous clinical trials dating back to the 1980s have explored the use of Ta1 in combination with various chemotherapeutics compared to control groups. In a Cochrane review²⁷ from 2011 analyzing Ta1's use in randomized controlled trials of cancer treatment, three trials with specific safety monitoring included 56 patients. The reported adverse events, such as mild nausea, fatigue, and burning at the injection site, all resolved without sequelae.

Indeed, trends toward clinical benefits were observed in terms of reduced risk of mortality and higher disease-free

survival. A 2019 review encompassing four clinical trials on non-small cell lung carcinoma (NSCLC) involving 320 patients treated with Ta1 revealed at least a trend toward treatment efficacy, and Ta1 was well-tolerated.²⁸⁻³² Subsequently, a more recent meta-analysis³³ of 27 studies reaffirmed the safety of Ta1 among NSCLC users. Out of these 27 studies, 20 utilized Ta1, while the remaining studies employed a different thymus peptide than Ta1. In 2021, a propensity score-matched analysis³⁴ involving 1027 patients found no new safety signals from Ta1 use, concluding it to be both safe and beneficial for patients.

Clinical trials have investigated the use of Ta1 in breast and colon cancer. In a study³⁵ involving 36 patients with invasive ductal breast cancer, those administered Ta1 alongside chemotherapy reported experiencing less pain and fewer side effects associated with a compromised immune system compared to those receiving chemotherapy alone. Another study,³⁶ focusing on 22 patients with advanced breast cancer, employed a dosage of 1.6 mg/day of Ta1 for 4 days before chemotherapy, followed by 1.6 mg twice weekly for 1-3 weeks afterward. Notably, this regimen demonstrated a reduction in neurotoxicity resulting from chemotherapy.

Regarding the mechanism of Ta1, a study³⁷ demonstrated that Ta1 induced apoptosis through the mitochondrial death cascade and inhibited the PI3K/Akt/mTOR signaling pathway in breast cancer cells. In the context of colorectal cancer, Ta1 was employed in a study involving 200 patients undergoing chemotherapy. The findings revealed that Ta1 improved the perioperative immune function of colorectal patients, reduced the incidence of postoperative complications, and increased the rate of disease-free survival, with no mention of discontinuing therapy.³⁸

Melanoma is another cancer that has been extensively studied for the efficacy and safety of Ta1. Considering the rising concerns over side effects and diminishing efficacy of immunotherapy, this immune-modulatory approach is gaining attention. Earlier in the 1990s, Ta1 was investigated as a 'Biochemotherapeutic' to enhance the immune targeting of cancer. In one study³⁹ involving 46 patients with metastatic melanoma, there was no observed overlapping toxicity or interference between Ta1 and dacarbazine chemotherapy and no increased toxicity from the combination.

In a study⁴⁰ from 2015, Ta1 was highlighted as central and strongly recommended for cases related to melanoma. A larger study⁴¹ utilizing Ta1 in melanoma, involving 488 patients treated with dacarbazine with or without interferon-alpha, demonstrated that Ta1 was safe, with no noted adverse effects. Another study⁴² involving Ta1 in combination with an immune checkpoint blockade antibody, Ipilimumab, for metastatic melanoma followed patients for almost five years and revealed a longer survival rate with the combination of both medications, with no adverse effects noted for Ta1.

Hepatocellular carcinoma resulting from chronic hepatitis is another cancer investigated with Ta1 as a hopeful treatment option. Multiple clinical trials on hepatitis B and C, exploring the use and safety of this peptide, reveal a reduction in the hepatitis burden, thereby decreasing

progression to cancer.⁴³ Ta1 not only has the potential to contribute to cancer therapy directly but also to its prevention.

In a retrospective study,⁴⁴ 146 patients received Ta1 after hepatic surgery for hepatocellular cancer arising from hepatitis B. The results suggested that post-hepatectomy Ta1 therapy improves liver function and significantly prolongs recurrence-free and overall survival in patients with HBV-associated hepatocellular cancer. Several studies have explored the use of Ta1 for unresectable hepatocellular cancer in patients who are not candidates for surgery but have tumors small enough for ablative therapy or transarterial chemoembolization (TACE). TACE may prolong survival, and the addition of Ta1, along with an excellent safety profile, improved outcomes.⁴⁵⁻⁴⁶ Additionally, incorporating Ta1 with lamivudine proves helpful in post-operative treatment to prevent recurrence.⁴⁷

Ta1 Efficacy Against Autoimmune Diseases

Presently, there are over 100 autoimmune (AI) diseases, a significant increase compared to just a few decades ago.⁴⁸ Studies have illustrated that environmental toxins and the microbiome contribute to this rise. AI conditions are characterized by abnormal T-cell signaling, thus promoting systemic diseases. Furthermore, individuals with AI diseases have been noted to exhibit significantly lower circulating Ta1 levels than healthy subjects, highlighting immune dysregulation.⁴⁹ The growing trend of younger individuals developing AI conditions is alarming. The primary treatment approach involves immunosuppressives, which, unfortunately, do not effectively address the core of the disease and pose the risk of serious adverse events with prolonged use.⁵⁰

Among AI diseases, Multiple Sclerosis (MS) affects more than 2.5 million people worldwide. In experimental animal models of MS, both Ta1 and Thymosin Beta 4 (a 43-amino acid peptide also derived from the thymus gland) have demonstrated efficacy in aiding myelin repair and providing neuronal protection. The authors suggest the necessity for human trials, considering this promising history.⁵¹ Meanwhile, autoimmune disorders have already shown benefit from the effects of Ta1. For instance, a recent publication highlighted a pediatric patient with Crohn's disease who achieved complete clinical remission beyond one year after the introduction of Ta1, succeeding where other treatment options had failed.⁵²

Apart from the recovery, no side effects were reported, demonstrating that Ta1 helped prevent unnecessary and harmful effects of long-standing immunosuppression. In another study⁵³ involving chronic idiopathic thrombocytopenic purpura, the combination of Ta1 with a high dose of dexamethasone proved more beneficial for 30 out of 39 (77%) patients compared to 12 out of 27 (44%) patients who received only a high dose of dexamethasone. Additionally, the Ta1 group exhibited a significantly lower relapse rate, with no documented cessation of therapy or harm noted.

The clinical applications for Ta1 are extensive, especially concerning the importance of recognizing the temporal

association between autoimmune disease flares after COVID-19 vaccinations.⁵⁴ In line with its well-established safety profile, Ta1 not only proved to be safe but also showed some clinical benefits in most studies.

FUTURE IMPLICATIONS

Addressing Age-Related Decline and Enhancing Endogenous Function

Aging is associated with a decline in the immune system, leading to greater susceptibility to infectious diseases, a poorer response to vaccination, and an increased prevalence of cancer, autoimmune, and other chronic diseases. The state of the immune system can be assessed through a blood test measuring the CD4/CD8 ratio of T-helper cells to cytotoxic T-cells. A normal CD4/CD8 ratio ranges from 1 to 3, while a low CD4/CD8 ratio below 1 indicates an impaired immune system. The prevalence of an inverted CD4/CD8 ratio increases with age.⁵⁵ Ta1 has been demonstrated to improve the CD4/CD8 ratio, effectively enhancing endogenous immune function.⁵⁶

Targeting Toll-Like Receptors and Enhancing Adaptive Immune Responses

Ta1 serves as a potent modulator of immunity and inflammation, operating as a toll-like receptor (TLR)-9 and TLR-2 agonist in both myeloid and dendritic cells.⁵⁷⁻⁵⁸ By targeting TLRs, Ta1 can activate the adaptive immune response, which is crucial for combating viral, bacterial, and fungal infections, as well as cancers.¹ Furthermore, Ta1 has the capacity to elevate levels of IL-2, IL-10, IL-12, interferon (IFN)- α , and IFN- γ .⁵⁹ Its role in stimulating T-cell-dependent antibody production positions Ta1 as a potential vaccine adjuvant for enhancing responses to vaccines.

Activating T-Cells and Suppressing Inflammatory Responses

Ta1 plays an important role in activating T-cells into mature CD4 and CD8 cells with its immune-modulating properties. Ta1 directly stimulates natural killer cells and CD8 cells, enhancing their ability to eliminate virally infected cells. Moreover, its inhibitory impact on IL-1 β and tumor necrosis factor- α contributes to a reduced inflammatory response.⁶⁰

Harnessing Ta1 for a Paradigm Shift in Medicine

Aging contributes to immune dysfunction, marked by thymus gland atrophy and reduced Ta1 production. Research indicates lower Ta1 levels in individuals with autoimmune diseases compared to healthy controls. This finding prompts a paradigm shift in medical approaches. Rather than exclusively addressing infectious diseases, autoimmunity, or cancer, leveraging Ta1 emerges as a transformative strategy to maintain immune system health, ushering in a new era of medicine.

Ta1 Potential for Immune Dysfunction

Ta1 has proven beneficial for numerous patients struggling with compromised immune systems, spanning

infections, autoimmune diseases, and cancer. A survey of 503A compounded pharmacies, which dispense Ta1 prescriptions, revealed that over 500 000 Americans have embraced this treatment without encountering severe side effects. As systems biology medicine gains traction, there is a compelling case to research deeper into the potential of Ta1, advocating for its widespread utilization as a potent tool against immune dysfunction.

Safety and Future Promise of Ta1 in Addressing Immune Dysregulation

Ta1 emerges as a beacon of hope, highlighting its substantial benefits and flawless safety record. Notably, no documented concerns for harm or drug-drug interactions have been identified, positioning Ta1 as a promising solution for patients grappling with challenging medical conditions rooted in immune dysregulation. However, the disconcerting FDA scrutiny of Ta1, along with other proven peptides, raises significant apprehensions. Unlike many medications, Ta1 has navigated preclinical development, large phase 3 clinical studies, and current medical practice seamlessly, with no reported instances of misuse or harm in the extensive literature review.

The recent FDA ban on peptides, including Ta1, raises concerns about potential implications. If the ban persists, the public may turn to online sources that claim to provide peptides “for research purposes only,” introducing uncertainty about their quality. This situation poses a significant risk to patient safety. Instead, ensuring a stable supply for healthcare providers by allowing regulated compounding pharmacies to continue their operations is a more prudent approach. These pharmacies adhere to rigorous quality control standards and accreditation requirements established by the FDA. Regular site visits, compliance with quality control measures, and specialty certifications are integral parts of their practice. Protecting the existence of 503A compounding pharmacies is crucial to ensure the continued production of safe and sterile Ta1 in accordance with the FDA’s stringent standards.

CONCLUSION

In conclusion, Ta1 has demonstrated its safety with over 11 000 subjects enrolled and clinically evaluated in high-quality studies, with no significant harm ever reported. Ta1 has proven lifesaving when used to treat various conditions without resulting in long-term complications or interactions seen with other medications. Studies of Ta1 have increased exponentially, as reflected in the literature, supporting its continued use and exploration for additional treatment options. Post-marketing surveillance, based on the experience of more than 600 000 treated patients with this peptide, affirms Ta1’s excellent tolerability. Discontinuing its compounding would likely cause more harm than good.

Therefore, clinicians should retain access to such treatment options and have the authority to prescribe them based on evidence-based medicine, free from undue influence. Unless there is a substantiated case against a therapy, the removal of the ability to compound or produce a substance like Ta1 is

unwarranted. Numerous pharmaceuticals have gained approval with far less safety data, only to be withdrawn from the market later due to harmful effects. Disallowing this drug would create a double standard and raise ethical concerns. Ta1 should be permitted for compounding by a 503A compounding pharmacy because it holds treatment implications across multiple medical specialties and has established a long-term safety profile to meet patient needs.

COMPETING INTERESTS

The authors report no conflict of interest.

AVAILABILITY OF DATA AND MATERIALS

The data that support the findings of this study are available from the corresponding author upon reasonable request.

FUNDING

None.

ACKNOWLEDGEMENTS

None.

REFERENCES

- Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. *Ann N Y Acad Sci.* 2007;1112(1):326-338. PMID:17495242 doi:10.1196/annals.1415.002
- Camerini R, Garaci E. Historical review of thymosin α 1 in infectious diseases. *Expert Opin Biol Ther.* 2015;15(sup1)(suppl 1):S117-S127. PMID:26098768 doi:10.1517/14712598.2015.1033393
- <https://www.accessdata.fda.gov/scripts/opdlisting/ood/listResult.cfm>
- King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. *Vitam Horm.* 2016;102:151-178. PMID:27450734 doi:10.1016/bs.vh.2016.04.003
- Shang W, Zhang B, Ren Y, Wang W, Zhou D, Li Y. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. *Int Immunopharmacol.* 2023;114:109584. PMID:36527881 doi:10.1016/j.intimp.2022.109584
- Shehadeh F, Benitez G, Mylona EK, et al. A Pilot Trial of Thymalfasin (Thymosin- α -1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. *J Infect Dis.* 2023;227(2):226-235. PMID:36056913 doi:10.1093/infdis/jiac362
- Liu Y, Pan Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. *Clin Infect Dis.* 2020;71(16):2150-2157. PMID:32442287 doi:10.1093/cid/cia630
- Tuthill CW, Awad A, Parrigon M, Ershler WB. A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: preliminary report. *Int Immunopharmacol.* 2023;117:109950. PMID:36881981 doi:10.1016/j.intimp.2023.109950
- Soeroto AY, Suryadinata H, Yanto TA, Hariyanto TI. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. *Inflammopharmacology.* 2023;31(6):3317-3325; Epub ahead of print. PMID:37845598 doi:10.1007/s10787-023-01354-2
- Wang Z, Chen J, Zhu C, et al. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients. *Front Immunol.* 2021;12:568789. doi:10.3389/fimmu.2021.568789
- Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. *Crit Care.* 2013;17(1):R8. PMID:23327199 doi:10.1186/cc11932
- Li C, Bo L, Liu Q, Jin F. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. *Int J Infect Dis.* 2015;33:90-96. PMID:25532482 doi:10.1016/j.ijid.2014.12.032
- You J, Zhuang L, Cheng HY, et al. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. *World J Gastroenterol.* 2006;12(41):6715-6721. PMID:17075991 doi:10.3748/wjg.v12.i41.6715
- Peng D, Xing HY, Li C, et al. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. *BMC Gastroenterol.* 2020;20(1):348. PMID:33076834 doi:10.1186/s12876-020-01477-8
- Lau GK, Nanji A, Hou J, et al. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. *J Viral Hepat.* 2002;9(4):280-287. PMID:12081605 doi:10.1046/j.1365-2893.2002.00361.x
- Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. *Viral J.* 2009;6(1):63. PMID:19467157 doi:10.1186/1743-422X-6-63
- Andreone P, Cursaro C, Gramenzi A, et al. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. *Liver.* 1996;16(3):207-210. PMID:8873009 doi:10.1111/j.1600-0676.1996.tb00729.x
- Rasi G, DiVirgilio D, Mutchnick MG, et al. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C. *Gut.* 1996;39(5):679-683. PMID:9026482 doi:10.1136/gut.39.5.679
- Moscarella S, Buzzelli G, Romanelli RG, et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. *Liver.* 1998;18(5):366-369. PMID:9831367 doi:10.1111/j.1600-0676.1998.tb00819.x
- Ciancio A, Andreone P, Kaiser S, et al. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? *J Viral Hepat.* 2012;19(s1)(suppl 1):52-59. PMID:22233415 doi:10.1111/j.1365-2893.2011.01524.x
- Baek YH, Lee SW, Yoo HS, et al. Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment. *Gut Liver.* 2007;1(1):87-89. PMID:20485665 doi:10.5009/gnl.2007.1.1.87

22. Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. *Hepatology*. 1998;27(4):1128-1135. PMID:9537454 doi:10.1002/hep.510270430
23. Poo JL, Sánchez Avila F, Kershenovich D, et al. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. *Ann Hepatol*. 2008;7(4):369-375. PMID:19034238 doi:10.1016/S1665-2681(19)31839-3
24. Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, Merigan TC. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. *J Infect Dis*. 1996;173(4):1005-1008. PMID:8603940 doi:10.1093/infdis/173.4.1005
25. Garaci E, Milanese G, Vella S, et al. A randomised controlled study for the evaluation of the activity of a triple combination of zidovudine, thymosin- α 1 and interferon- α in HIV-infected individuals with CD4 counts between 200 and 500 cells/mm³. *Antivir Ther*. 1998;3(2):103-111. doi:10.1177/135965359800300203
26. Chadwick D, Pido-Lopez J, Pires A, et al. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. *Clin Exp Immunol*. 2003;134(3):477-481. PMID:14632754 doi:10.1111/j.1365-2249.2003.02331.x
27. Wolf E, Milazzo S, Boehm K, Zwalen M, Horneber M. Thymic peptides for treatment of cancer patients. *Cochrane Database Syst Rev*. 2011;2011(2):CD003993. PMID:21328265 doi:10.1002/14651858.CD003993.pub3
28. Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. *Front Oncol*. 2019;9:873. doi:10.3389/fonc.2019.00873
29. Schulof RS, Lloyd MJ, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. *J Biol Response Mod*. 1985;4(2):147-158. PMID:3998766
30. Garaci E, Lopez M, Bonsignore G, et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. *Eur J Cancer*. 1995;31A(13-14):2403-2405. PMID:8652276 doi:10.1016/0959-8049(95)00477-7
31. Salvati F, Rasi G, Portalone L, Antilli A, Garaci E. Combined treatment with thymosin-alpha 1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. *Anticancer Res*. 1996;16(2):1001-1004. PMID:8687090
32. Jiang J, Wang X, Tian J, Li L, Lin Q. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. *Thorax Cancer*. 2011;2(4):213-220. PMID:27755854 doi:10.1111/j.1759-7714.2011.00057.x
33. Zeng F-L, Xiao Z, Wang C-Q, et al. Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. *International Immunopharmacology*. Volume 75, 2019, 105747, ISSN 1567-5769 doi:10.1016.
34. Guo CL, Mei JD, Jia YL, et al. Impact of thymosin α 1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis. *Chin Med J (Engl)*. 2021;134(22):2700-2709. PMID:34732663 doi:10.1097/CM9.0000000000001819
35. Dou D, Tao W, Li L, et al. Immuno-stabilizing effect of thymosin-alpha-1 on post- modified radical mastectomy (MRM) of breast cancer patients. *Afr J Pharm Pharmacol*. 2011;5(22):2428-2434. doi:10.5897/AJPP11.168
36. An TT, Liu XY, Fang J, Wu MN. Primary assessment of treatment effect of thymosin alpha1 on chemotherapy-induced neurotoxicity. *Ai Zhong*. 2004 Nov;23(11 Suppl):1428-30. Chinese. PMID: 15566650.
37. Guo Y, Chang H, Li J, et al. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway. *Apoptosis*. 2015;20(8):1109-1121. PMID:26002438 doi:10.1007/s10495-015-1138-9
38. Niu W, Li Z, Li Z, et al. A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer. *Biotechnol Genet Eng Rev*. 2023;***:1-13; Epub ahead of print. PMID:37248723 doi:10.1080/02648725.2023.2216972
39. Lopez M, Carpano S, Cavaliere R, et al. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. *Ann Oncol*. 1994;5(8):741-746. PMID:7826907 doi:10.1093/oxfordjournals.annonc.a058979
40. Garaci E, Pica F, Matteucci C, et al. Historical review on thymosin α 1 in oncology: preclinical and clinical experiences. *Expert Opin Biol Ther*. 2015;15(sup1)(suppl 1):S31-S39. PMID:26096345 doi:10.1517/14712598.2015.1017466
41. Maio M, Mackiewicz A, Testori A, et al; Thymosin Melanoma Investigation Group. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. *J Clin Oncol*. 2010;28(10):1780-1787. PMID:20194853 doi:10.1200/JCO.2009.25.5208
42. Danielli R, Cisternino F, Giannarelli D, Calabrò L, Camerini R, Savelli V, Bova G, Dragonetti R, Di Giacomo AM, Altomonte M, Maio M. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy. *Expert Opin Biol Ther*. 2018 Jul;18(sup1):77-83. doi:10.1080/14712598.2018.1494717. PMID: 30063847.
43. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. *Hepatology*. 1991;14(3):409-415. doi:10.1002/hep.1840140302
44. Liang YR, Guo Z, Jiang JH, Xiang BD, Li LQ. Thymosin α 1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. *Oncol Lett*. 2016;12(5):3513-3518. PMID:27900029 doi:10.3892/ol.2016.5121
45. Shuqun C, Mengchao W, Han C, et al. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. *Hepatogastroenterology*. 2004;51(59):1445-1447. PMID:15362772
46. Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. *Hepatogastroenterology*. 1998;45(19):209-215. PMID:9496515
47. Shuqun C, Mengchao W, Han C, et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. *Hepatogastroenterology*. 2006;53(68):249-252.
48. Dinse GE, Parks CG, Weinberg CR, et al. Increasing prevalence of antinuclear antibodies in the United States. *Arthritis Rheumatol*. 2020;72(6):1026-1035. doi:10.1002/art.41214
49. Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases. *Clin Exp Immunol*. 2016;186(1):39-45. PMID:27350088 doi:10.1111/cei.12833
50. Chandrashekar S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. *Indian J Pharmacol*. 2012;44(6):665-671. PMID:23248391 doi:10.4103/0253-7613.103235
51. Severa M, Zhang J, Giacomini E, et al. Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application. *Mult Scler Relat Disord*. 2019;27:52-60. PMID:30317071 doi:10.1016/j.msard.2018.09.035
52. Dinetz E, Saleeby Y, Borrelia Burgdorferi, a Root Cause of Inflammatory Bowel Disease: A Case Report of Successful Treatment and Remission. *Altern Ther Health Med*. 2023;29(5):86-89. PMID:37392196
53. Wang L, Guo CS, Hou M, Li LZ, Zhang CQ, Chen F, Qin P, Peng J, He WD, Chu XX. Combination therapy of thymosin alpha1 and high dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. *Zhonghua Nei Ke Za Zhi*. 2007 Apr;46(4):274-6. Chinese. PMID: 17637261.
54. Nistri R, Barbuti E, Rinaldi V, et al. Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases. *Front Neurol*. 2021;12:765954. doi:10.3389/fneur.2021.765954
55. Wikby A, Månsson IA, Johansson B, Strindhall J, Nilsson SE. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age. *Biogerontology*. 2008;9(5):299-308. doi:10.1007/s10522-008-9138-6
56. Wu L, Luo PB, Tian YH, Chen LY, Zhang YL. Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes. *Pak J Med Sci*. 2022;38(1):179-184. PMID:35035422 doi:10.12669/pjms.38.1.4419
57. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. *Blood*. 2004;103(11):4232-4239. doi:10.1182/blood-2003-11-4036
58. Naylor PH, Quadri K, Garaci E, Rasi G, Hadden JW. Immunopharmacology of thymosin alpha1 and cytokine synergy. *Ann N Y Acad Sci*. 2007;1112(1):235-244. doi:10.1196/annals.1415.036
59. Tuthill C, Rios I, De Rosa A, Camerini R. Thymosin α 1 continues to show promise as an enhancer for vaccine response. *Ann N Y Acad Sci*. 2012;1270(1):21-27. doi:10.1111/j.1749-6632.2012.06680.x
60. Li J, Liu CH, Wang FS. Thymosin alpha 1: biological activities, applications and genetic engineering production. *Peptides*. 2010;31(11):2151-2158. doi:10.1016/j.peptides.2010.07.026
61. Li X, Liu L, Yang Y, et al. Gender-associated difference following COVID-19 virus infection: implications for thymosin alpha-1 therapy. *Int Immunopharmacol*. 2021;90:107022. doi:10.1016/j.intimp.2020.107022
62. Liu F, Wang HM, Wang T, Zhang YM, Zhu X. The efficacy of thymosin α 1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. *BMC Infect Dis*. 2016;16(1):488. doi:10.1186/s12879-016-1823-5
63. Lin M, et al. Thymosin-alpha1 and famciclovir combination therapy activate T-cell response in patients with chronic hepatitis B virus infection in the immune-tolerant phase. *J Viral Hepat*. 2002.
64. Linye H, et al. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis. *Medicine (Baltimore)*. 2021 May doi:10.1097/MD.00000000000025749
65. Shuqun C, Mengchao W, Han C, et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. *Hepatogastroenterology*. 2006;53(68):249-252.
66. Rasi G, Terzoli E, Izzo F, et al. Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma. *Melanoma Res*. 2000;10(2):189-192. doi:10.1097/00008390-200010020-00012
67. Niu W, Li Z, Li Z, et al. A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer. *Biotechnol Genet Eng Rev*. 2023;1-13. doi:10.1080/02648725.2023.2216972